Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Dow
Boehringer Ingelheim
Medtronic
AstraZeneca

Last Updated: November 15, 2019

DrugPatentWatch Database Preview

Litigation Details for DAIICHI SANKYO COMPANY, LIMITED v. MYLAN PHARMACEUTICALS, INC. (D.N.J. )

See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in DAIICHI SANKYO COMPANY, LIMITED v. MYLAN PHARMACEUTICALS, INC.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for DAIICHI SANKYO COMPANY, LIMITED v. MYLAN PHARMACEUTICALS, INC. (D.N.J. )

Date Filed Document No. Description Snippet Link To Document
2009-07-30 139 ARB compounds in United States Patent No. 5,138,069 (“the ‘069 patent”). (Weinstock 3/31/09 Tr. JA 119…States Patent No. 5,616,599 (“the ‘599 patent”). Mylan concedes infringement of the ‘599 patent, but …that the ‘599 patent is obvious under 35 U.S.C. § 103(a). As a result, the ‘599 patent is neither invalid…This led to the issuance the ‘599 patent by the United States Patent and Trademark Office (“PTO”) on April…‘902 patent compounds, as well as DuP 532. Following the disclosure of the ‘069 patent compounds External link to document
2016-10-20 161 infringement of its United States Patent No. 5,616,599 (“the ‘599 patent”). Mylan conceded infringement…599 patent undisputedly expired on April 25, 2016 . . . .”); Def.’s Opp’n at 1 (“The ‘599 patent expired…expiration date of the ‘599 patent” and “until the expiration date of the ‘599 patent.” See Pls.’ Br. at 5–…of six months after the date the patent expires (including any patent extensions)[.]” See id. at 4 (citing…exclusivity attaching to the end of a patent term is not a patent term extension under 35 U.S.C. § 156 External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Moodys
Colorcon
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.